Short Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Declines By 16.2%

Lyell Immunopharma, Inc. (NASDAQ:LYEL) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 8,090,000 shares, a drop of 16.2% from the February 13th total of 9,650,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is presently 7.0 days. Currently, 6.5% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a report on Thursday, March 13th.

Lyell Immunopharma Stock Down 5.8 %

Shares of NASDAQ:LYEL traded down $0.03 on Tuesday, hitting $0.49. 550,649 shares of the company traded hands, compared to its average volume of 1,040,421. The stock has a 50 day simple moving average of $0.62 and a 200-day simple moving average of $0.90. The company has a market cap of $143.78 million, a PE ratio of -0.62 and a beta of -0.41. Lyell Immunopharma has a 52 week low of $0.48 and a 52 week high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. As a group, sell-side analysts anticipate that Lyell Immunopharma will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LYEL. Barclays PLC lifted its holdings in shares of Lyell Immunopharma by 7.4% during the fourth quarter. Barclays PLC now owns 258,380 shares of the company’s stock valued at $165,000 after purchasing an additional 17,765 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Lyell Immunopharma by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company’s stock valued at $60,000 after acquiring an additional 20,542 shares during the last quarter. Centiva Capital LP bought a new stake in shares of Lyell Immunopharma in the third quarter worth approximately $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Lyell Immunopharma by 13.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock worth $197,000 after acquiring an additional 36,555 shares during the period. Finally, Intech Investment Management LLC bought a new position in Lyell Immunopharma during the third quarter valued at approximately $52,000. 66.05% of the stock is owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.